5 Stocks Dragging The Health Services Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 44 points (-0.3%) at 15,836 as of Monday, Jan. 27, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 751 issues advancing vs. 2,176 declining with 155 unchanged.

The Health Services industry currently sits down 2.0% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Align Technology ( ALGN), down 6.6%, Opko Health ( OPK), down 4.7%, Grifols ( GRFS), down 2.3%, C.R. Bard ( BCR), down 1.9% and Agilent Technologies ( A), down 1.2%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Hologic ( HOLX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Hologic is down $0.33 (-1.6%) to $20.91 on light volume. Thus far, 689,010 shares of Hologic exchanged hands as compared to its average daily volume of 4.4 million shares. The stock has ranged in price between $20.82-$21.30 after having opened the day at $21.26 as compared to the previous trading day's close of $21.24.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women. Hologic has a market cap of $6.0 billion and is part of the health care sector. Shares are down 5.0% year-to-date as of the close of trading on Friday. Currently there are 6 analysts that rate Hologic a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Hologic as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Hologic Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Edwards Life ( EW) is down $3.27 (-4.8%) to $65.54 on average volume. Thus far, 923,627 shares of Edwards Life exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $65.12-$68.71 after having opened the day at $68.43 as compared to the previous trading day's close of $68.81.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Life has a market cap of $7.5 billion and is part of the health care sector. The company has a P/E ratio of 19.4, above the S&P 500 P/E ratio of 17.7. Shares are up 4.6% year-to-date as of the close of trading on Friday. Currently there are 6 analysts that rate Edwards Life a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Edwards Life as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Edwards Life Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, DaVita HealthCare Partners ( DVA) is down $0.60 (-0.9%) to $63.60 on light volume. Thus far, 335,492 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $63.50-$64.11 after having opened the day at $64.11 as compared to the previous trading day's close of $64.20.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $14.0 billion and is part of the health care sector. The company has a P/E ratio of 24.7, above the S&P 500 P/E ratio of 17.7. Shares are up 1.3% year-to-date as of the close of trading on Friday. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, St Jude Medical ( STJ) is down $0.68 (-1.1%) to $61.43 on average volume. Thus far, 1.2 million shares of St Jude Medical exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $61.13-$62.76 after having opened the day at $62.67 as compared to the previous trading day's close of $62.11.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in two divisions, Cardiovascular and Ablation Technologies, and Implantable Electronic Systems. St Jude Medical has a market cap of $18.6 billion and is part of the health care sector. The company has a P/E ratio of 17.0, below the S&P 500 P/E ratio of 17.7. Shares are up 0.3% year-to-date as of the close of trading on Friday. Currently there are 11 analysts that rate St Jude Medical a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full St Jude Medical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Boston Scientific ( BSX) is down $0.21 (-1.6%) to $13.13 on light volume. Thus far, 3.2 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 11.3 million shares. The stock has ranged in price between $13.07-$13.39 after having opened the day at $13.35 as compared to the previous trading day's close of $13.34.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $18.2 billion and is part of the health care sector. Shares are up 11.0% year-to-date as of the close of trading on Friday. Currently there are 7 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Boston Scientific as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Boston Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home